

An exploratory conformational analysis of 3-mercapto-propanamide and 2-methyl-3-mercapto-propanamide as well as their *S*-deprotonated conjugate basis: an ab initio study

L.L. Torday^{a,*}, B. Penke^b, G. Zamarbide^c, R.D. Enriz^c, J.Gy. Papp^a

^aDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical University, Dóm tér 12.,
H-6701 Szeged, Hungary

^bDepartment of Medical Chemistry, Albert Szent-Györgyi Medical University, Dóm tér 8. H-6701 Szeged, Hungary

^cDepartment de Química, Universidad Nacional de San Luis, 5700 San Luis, Argentina

Received 22 November 1999; accepted 20 December 1999


Abstract

Ab initio conformational analysis has been carried out on 3-mercapto-propanamide, (*R*)- and (*S*)-2-methyl-3-mercapto-propanamide as well as their *S*-deprotonated conjugate basis. They were carried out at the HF/3-21G level of theory. The topology of the conformational potential energy surfaces and hypersurfaces have been analysed. © 2000 Elsevier Science B.V. All rights reserved.

Keywords: 3-Mercapto-propanamide; (*R*)- and (*S*)-2-methyl-3-mercapto-propanamide; *S*-deprotonated conjugate basis

1. Introduction

Captopril [**1**] an effective antihypertensive drug [1–4] is a relatively small molecule which may be in its biologically active dianion [**1b**] or neutral form [**1a**]. It has several functional groups and the molecule may assume numerous stable conformations. Consequently, captopril [**1**] can interact regio and stereospecifically with various functional groups present at the active site of the angiotensin converting enzyme (ACE) [1–4] as illustrated schematically, by Fig. 1.



Since no X-ray structure of ACE is available one does not know the stereochemical separations of the various sites of the enzyme, involved in the action mechanism. Captopril as an ACE-inhibitor may be used as a “molecular calliper” to estimate the upper and lower bound values for the separation *d* shown in Fig. 1.

Captopril has been studied [5] by a “classical potential energy” force field type method as early as 1985.

* Corresponding author. Fax: + 36-62-45-45-65.




Fig. 1. Docking model for ACE with substrate peptide (top) and captopril (bottom).

Subsequently Hillier et al. [6] carried out AM1 computations on this molecule in 1991. This was followed by Luke in 1994. Luke [7] also reported [8] AM1 calculations on the demethylated analogue of captopril in 1995. As far as it can be ascertained no




Fig. 2. Expected conformations (top) and computed relative energies, ΔE (kcal/mol) (bottom) of *S*-deprotonated 3-mercapto-propanamide structures.




Fig. 3. Expected conformations (top) and computed relative energies, ΔE (kcal/mol) (bottom) of *R* and *S* enantiomers of *S*-deprotonated 2-methyl-3-mercapto-propanamide structures.

ab initio calculations have been reported as yet on captopril.

2. Method

Ab initio computations have been carried out at the HF/3-21G level of theory, using the GAUSSIAN 94 software [9].


3. Results and discussion

Captopril poses a non-trivial multidimensional conformational problem. One of the conformational intricacies is associated with the five-member ring of the proline moiety. The $-\text{CO}-\text{NH}<$ moiety may be of *cis* or *trans* configurations. The five-member ring may be in a number of non-planar conformations. Finally the $-\text{COOH}$ moiety of [1a] could assume three

Table 1


Computed conformational characteristics of S-deprotonated 3-mercapto-propanamide optimised at the HF/3-21G level of theory

	ϕ	ψ	ω	E_{total}	ΔE
g^+g^+	Not found				
g^+a	Not found				
g^+g^-	78.79	-46.17	-177.29	-640.6483579	0.00
ag^+	-175.19	66.76	175.02	-640.6356826	7.95
aa	-180.00	179.98	-179.98	-640.6313114	10.70
ag^-	175.19	-66.75	-175.02	-640.6356825	7.95
g^-g^+	-78.76	46.21	177.22	-640.6483579	0.00
g^-a	Not found				
g^-g^-	Not found				



conformations (g^+ , a , g^-) leading to γ_L , ϵ_L , and α_L peptide foldings.

The other conformational variations of captopril [1] are residing in the flexible open chain which may be represented as 3-mercapto propanamide or its neutral form [2a] or S-deprotonated conjugate base [2b].



In these structures, the five member ring is omitted with respect to [1] and the hydrogen atoms are attached to the amide nitrogen.


Compounds [2a] and [2b] are also missing the

methyl group at the α -carbon (i.e. at C^2) with respect to [1]. If that methyl group is included then two enantiomers may be generated, (*S*)-2-methyl-3-mercapto-propanamide [3a] and its conjugate base [3b] as well as (*R*)-2-methyl-3-mercapto-propanamide [4a] and its conjugate base [4b].

Consequently, it seemed prudent to study the fragments [3b] and [5] of captopril [1] preferably related to its biologically active dianionic form [1b]. A derivative of [5], *N*-formyl-L-prolinamide [6] has already been studied [10] in a preliminary fashion.

The S-deprotonated forms of 3-mercapto-propanamide [2b] and (*S*)-2-methyl-3-mercapto-propanamide [3b] as well as (*R*)-2-methyl-3-mercapto-propanamide [4b] have been studied by the ab initio method at the HF/3-21G levels of theory. The results

for [2b] are shown in Fig. 2 and Table 1. It is interesting to note that the four annihilated minima (g^+g^+ , g^+a , g^-a , g^-g^-) correspond to the same four conformers annihilated in *N*-formyl-glycin-amide. In peptides (c.f. [7]) such an annihilation is traditionally rationalised [11] in terms of dipole/dipole repulsion.



The orientation at the bond moments in [7] and [8] seem to be analogous if not quite identical.


The introduction of methyl group at the α -carbon upsets the previous dipole/dipole repulsion [8] to such an extent [9] that another minimum (*a*, *a*) was annihilated. The results are shown in Fig. 3 and Table 2, for both the *S*- and *R*-enantiomers of [3b] and [4b], respectively.

moment. These may be seen by comparing [8], [10] and [11].

Since in [10] the H–S bond moment is further out than the C–S bond moment in [8], less repulsion is anticipated. Indeed, this is the case as shown in Fig. 4 and summarised in Table 3.

In the case of the 2-methylated compound [11] the introduction of the Me-group does not make any difference for the *anti*-oriented S–H conformation [$\theta = 180^\circ$] as may be seen in Fig. 5. However, it allows more minima for the $\theta = g^+$ and $\theta = g^-$ conformation as shown in Fig. 5 and in Tables 4 and 5.

The other fragment of captopril contains a proline residue. As discussed before such a residue could be



Considering the neutral forms of 3-mercapto-propanamide and the *R*- and *S*-enantiomers of 2-methyl-3-mercapto-propanamide one may anticipate some change due to the fact that the H–S bond moment will dominate over the C–S bond

studied in the form of *N*-formyl-prolinate [5]. So far we have investigated the conformational behaviour of *N*-formyl-prolinamide [6]. As it has to be emphasised that the five-member ring in the proline residue [12] allows the variable ϕ to be in the vicinity of g^- and

Table 2

Computed conformational characteristics of the *R*- and *S*-enantiomers of *S*-deprotonated 2-methyl-3-mercapto-propanamide optimised at HF/3-21G level of theory

	ϕ	ψ	ω	χ	E_{total}	$\Delta\Delta E$
<i>R</i> -enantiomer						
g^+g^+	Not found					
g^+a	Not found					
g^+g^-	79.39	-49.48	-174.38	65.92	-679.4712174	0.00
ag^+	170.75	51.27	174.45	61.01	-679.4575281	8.59
aa	Not found					
ag^-	165.45	-73.57	-175.37	54.73	-679.459622	7.28
g^-g^+	-73.78	46.38	174.67	69.36	-679.468885	1.46
g^-a	Not found					
g^-g^-	Not found					
<i>S</i> -enantiomer						
g^+g^+	Not found					
g^+a	Not found					
g^+g^-	73.78	-46.45	-174.58	-69.34	-679.4688851	1.46
ag^+	-165.43	73.57	175.31	-54.69	-679.4596221	7.28
aa	Not found					
ag^-	-170.81	-51.50	-174.41	-61.16	-679.4575282	8.59
g^-g^+	-79.39	49.53	174.43	-65.90	-679.4712174	0.00
g^-a	Not found					
g^-g^-	Not found					




Table 3

Computed conformational characteristics of the 3-mercapto-propanamide optimised at HF/3-21G level of theory

	θ	ϕ	ψ	ω	χ	E_{total}	ΔE	$\Delta\Delta E$
$g^+g^+g^+$	59.62	54.85	56.78	179.12	64.63	-680.0077715	3.71	4.96
g^+g^+a	75.46	70.88	-144.73	-175.96	59.04	-680.0124754	0.76	2.01
$g^+g^+g^-$	71.24	81.89	-64.46	-177.07	62.42	-680.0118538	1.15	2.40
g^+ag^+	81.75	169.72	66.10	-178.03	68.19	-680.0074814	3.89	5.15
g^+aa	86.80	175.44	-159.35	-177.50	61.92	-680.0118794	1.13	2.39
g^+ag^-	81.05	170.72	-82.77	176.21	56.72	-680.0113095	1.49	2.74
$g^+g^-g^+$	Not found							
g^+g^-a	70.57	-70.11	-173.72	-177.63	61.04	-680.0136855	0.00	1.25
$g^+g^-g^-$	43.64	-68.84	-89.11	178.25	53.86	-680.0107768	1.83	3.08
ag^+g^+	179.46	61.49	57.67	179.87	65.42	-680.0056264	3.69	6.31
ag^+a	Not found							
ag^+g^-	Not found							
aag^+	-167.67	172.23	65.53	-177.61	67.04	-680.0071222	2.75	5.37
aaa	-175.46	172.88	-164.66	-177.59	59.84	-680.0115057	0.00	2.62
aag^-	178.94	178.94	-82.57	176.34	53.19	-680.0103653	0.72	3.34
ag^-g^+	158.71	-83.27	47.96	-178.89	62.74	-680.0074613	2.54	5.16
ag^-a	Not found							
ag^-g^-	-179.15	-60.34	-67.24	-179.15	58.16	-680.0072888	2.65	5.27
$g^-g^+g^+$	-67.17	60.69	51.17	-174.96	64.34	-680.0078444	4.92	4.92
g^-g^+a	-75.82	68.03	-164.42	-176.67	60.54	-680.0156812	0.00	0.00
$g^-g^+g^-$	Not found							
g^-ag^+	-68.95	170.46	63.92	-177.96	64.23	-680.0089084	4.25	4.25
g^-aa	-72.75	174.08	-164.51	-178.44	58.36	-680.0123034	2.12	2.12
g^-ag^-	-68.76	173.93	-85.69	176.52	52.14	-680.0109917	2.94	2.94
$g^-g^-g^+$	-77.18	-77.25	59.64	177.16	62.88	-680.0086255	4.43	4.43
g^-g^-a	-99.88	-68.03	174.57	-178.75	56.18	-680.0088266	4.30	4.30
$g^-g^-g^-$	-70.55	-55.24	-61.77	176.60	56.78	-680.0087301	4.36	4.36




Table 4

Computed conformational characteristics of the (*S*)-2-methyl-3-mercapto-propanamide optimised at HF/3-21G level of theory

	θ	ϕ	ψ	ω	χ	E_{total}	ΔE	$\Delta\Delta E$
$g^+g^+g^+$	70.44	55.21	61.78	-176.63	-56.73	-680.0087301	4.36	4.36
g^+g^+a	99.80	68.03	-174.67	178.80	56.19	-680.0088266	4.30	4.30
$g^+g^+g^-$	77.26	77.29	-59.64	-177.17	-62.86	-680.0086256	4.43	4.43
g^+ag^+	68.76	-173.93	85.69	-176.52	-52.14	-680.0109917	2.94	2.94
g^+aa	72.65	-174.10	164.53	178.40	-58.38	-680.0123034	2.12	2.12
g^+ag^-	68.95	-170.46	-63.92	177.96	-64.23	-680.0089084	4.25	4.25
$g^+g^-g^+$	Not found							
g^+g^-a	75.80	-67.97	164.41	176.65	-60.73	-680.0156813	0.00	0.00
$g^+g^-g^-$	67.12	-60.71	-51.27	174.93	-64.47	-680.0078445	4.92	4.92
ag^+g^+	-180.85	60.34	67.24	-177.04	-58.16	-680.0072888	2.65	5.27
ag^+a	Not found							
ag^+g^-	-158.71	83.27	-47.96	178.89	-62.74	-680.0074613	2.54	5.16
$aaag^+$	-178.94	-169.07	82.53	-176.35	-53.18	-680.0103653	0.72	3.34
aaa	175.51	-172.86	164.66	177.54	-59.84	-680.0115057	0.00	2.62
$aaag^-$	-192.28	-172.20	-65.48	177.62	-66.91	-680.0071224	2.75	5.37
ag^-g^+	162.418	-89.84	53.79	-179.12	-64.44	-680.0105571	0.60	3.22
ag^-a	Not found							
ag^-g^-	-179.46	-61.51	-57.73	-179.83	-65.39	-680.0056265	3.69	6.31
$g^-g^+g^+$	-43.64	68.84	89.11	-178.25	-53.86	-680.0107768	1.82	3.08
g^-g^+a	-70.69	70.03	173.74	177.69	-60.93	-680.013685	0.00	1.25
$g^-g^+g^-$	Not found							
g^-ag^+	-81.05	-170.72	82.04	-176.20	-56.70	-680.0113096	1.49	2.74
g^-aa	-86.80	-175.44	159.35	177.50	-61.92	-680.0118794	1.13	2.39
g^-ag^-	-81.58	-169.72	-66.09	178.07	-68.29	-680.0074812	3.89	5.15
$g^-g^-g^+$	-71.25	-81.96	64.31	177.19	-62.61	-680.0118537	1.15	2.40
g^-g^-a	-75.46	-70.88	144.73	175.96	-59.04	-680.0124754	0.76	2.01
$g^-g^-g^-$	-59.68	-54.82	-56.83	-179.06	-64.63	-680.0077714	3.71	4.96





Table 5

Computed conformational characteristics of the (*R*)-2-methyl-3-mercapto-propanamide optimised at HF/3-21G level of theory

	θ	ϕ	ψ	ω	χ	E_{total}	ΔE	$\Delta\Delta E$
$g^+g^+g^+$	59.62	54.85	56.78	179.12	64.63	-680.0077715	3.71	4.96
g^+g^+a	75.46	70.88	-144.73	-175.96	59.04	-680.0124754	0.76	2.01
$g^+g^+g^-$	71.24	81.89	-64.46	-177.07	62.42	-680.0118538	1.15	2.40
g^+ag^+	81.75	169.72	66.10	-178.03	68.19	-680.0074814	3.89	5.15
g^+aa	86.80	175.44	-159.35	-177.50	61.92	-680.0118794	1.13	2.39
g^+ag^-	81.05	170.72	-82.77	176.21	56.72	-680.0113095	1.49	2.74
$g^+g^-g^+$	Not found							
g^+g^-a	70.57	-70.11	-173.72	-177.63	61.04	-680.0136855	0.00	1.25
$g^+g^-g^-$	43.64	-68.84	-89.11	178.25	53.86	-680.0107768	1.83	3.08
ag^+g^+	179.46	61.49	57.67	179.87	65.42	-680.0056264	3.69	6.31
ag^+a	Not found							
ag^+g^-	-162.42	89.84	-53.79	179.12	64.44	-680.0105571	0.60	3.22
aag^+	-167.67	172.23	65.53	-177.61	67.04	-680.0071222	2.75	5.37
aaa	-175.46	172.88	-164.66	-177.59	59.84	-680.0115057	0.00	2.62
aag^-	178.94	178.94	-82.57	176.34	53.19	-680.0103653	0.72	3.34
ag^-g^+	158.71	-83.27	47.96	-178.89	62.74	-680.0074613	2.54	5.16
ag^-a	Not found							
ag^-g^-	-179.15	-60.34	-67.24	-179.15	58.16	-680.0072888	2.65	5.27
$g^-g^+g^+$	-67.17	60.69	51.17	-174.96	64.34	-680.0078444	4.92	4.92
g^-g^+a	-75.82	68.03	-164.42	-176.67	60.54	-680.0156812	0.00	0.00
$g^-g^+g^-$	Not found							
g^-ag^+	-68.95	170.46	63.92	-177.96	64.23	-680.0089084	4.25	4.25
g^-aa	-72.75	174.08	-164.51	-178.44	58.36	-680.0123034	2.12	2.12
g^-ag^-	-68.76	173.93	-85.69	176.52	52.14	-680.0109917	2.94	2.94
$g^-g^-g^+$	-77.18	-77.25	59.64	177.16	62.88	-680.0086255	4.43	4.43
g^-g^-a	-99.88	-68.03	174.57	-178.75	56.18	-680.0088266	4.30	4.30
$g^-g^-g^-$	-70.55	-55.24	-61.77	176.60	56.78	-680.0087301	4.36	4.36







Fig. 4. Expected conformers (left) and computed energies: ΔE (kcal/mol) (right) of 3-mercapto-propanamide structures.

therefore along the variable ψ the amino acid backbone may only have three conformers (γ_L , ϵ_L and α_L) rather than the usual nine. This work has already been published [10]. However, there are additional complications. The nitrogen in proline has two alkyl group attached therefore one would expect similar energies to *cis*- and *trans*-peptide bonds in any proline residue [6]. This is in direct contrast to all naturally occurring amino acids. The problem has already been presented at the Fifth World Congress at WATOC [12] and further work is now in progress [13].







Fig. 5. Computed conformational energies, ΔE (kcal/mol) of 2-methyl-3-mercapto-propanamide.



The process of *cis-trans* isomerism may also be important in the docking of captopril. Clearly one would expect a different separation between the two negatively charged termini.

Obviously, d_{trans} represents a longer separation and d_{cis} a shorter separation. It may be anticipated that the separation (d_{ACE}) of the two points at the active site of the ACE cannot be shorter or larger than d_{cis} and d_{trans} , respectively:

$$d_{\text{cis}} < d_{\text{ACE}} < d_{\text{trans}}$$

In this sense captopril may be regarded to be a molecular “calliper” in establishing certain structural features of the ACE. Ab initio computations on the captopril, as a whole, has to wait until more computing power becomes available.

Acknowledgements

This work was supported by grant no. ETT 040/98 from the Hungarian Ministry of Welfare.

References

- [1] D.W. Cushman, H.S. Cheung, E.F. Sabo, M.A. Ondetti, *Biochemistry* 16 (1977) 9484.
- [2] S.H. Ferreira, *Br. J. Pharmacol. Chemother.* 24 (1956) 163.
- [3] Y.S. Bakhle, *Nature (London)* 220 (1968) 919.
- [4] Y.S. Bakhle, A.M. Reynard, J.R. Vane, *Nature (London)* 222 (1969) 956.
- [5] P.R. Andrews, J.M. Carson, A. Cassali, M.J. Spark, R. Woods, *J. Med. Chem.* 28 (1985) 393.
- [6] D.V.S. Green, I.H. Hillier, G.A. Morris, N. Gensmantel, D.W. Payling, D.H. Robinson, *J. Mol. Struct. (Theochem)* 251 (1991) 173.
- [7] B.T. Luke, *J. Mol. Struct. (Theochem)* 309 (1994) 1.
- [8] B.T. Luke, *J. Mol. Struct. (Theochem)* 332 (1995) 25.
- [9] M.J. Frisch, G.W. Trucks, H.B. Schlegel, M.W. Gill, B.G. Johnson, M.A. Robb, J.R. Cheeseman, T. Keith, G.A. Petersson, J.A. Montgomery, K. Raghavachari, M.A. Al-Laham, V.G. Zakrzewski, J.V. Ortiz, J.B. Foresman, J. Cioslowski, B.B. Stefanov, A. Nanayakkara, M. Challacombe, C.Y. Peng, P.Y. Ayala, W. Chen, M.W. Wong, J.L. Andres, E.S. Replogle, R. Gomperts, R.L. Martin, D.J. Fox, J.S. Binkley, D.J. Defrees, J. Baker, J.P. Stewart, M. Head-Gordon, C. Gonzalez, J.A. Pople, *GAUSSIAN 94*, Revision D.2, Gaussian Inc., Pittsburgh PA, 1995.
- [10] H.A. Baldoni, A.M. Rodrigues, G. Zamarbide, R.D. Enriz, Ö. Farkas, P. Csaszar, L.L. Torday, C.P. Sosa, I. Jakli, A. Perczel, M. Hollosi, I.G. Csizmadia, *J. Mol. Struct. (Theochem)* 465 (1999) 79.
- [11] A. Perczel, J.G. Angyan, M. Kajtar, W. Viviani, J.L. Rivail, J.F. Marcoccia, I.G. Csizmadia, *J. Am. Chem. Soc.* 113 (1991) 6256.
- [12] WATOC (99) Book of Abstracts, Paper: p 212.
- [13] H.A. Baldoni, G. Zamarbide, R.D. Enriz, L.L. Torday, Ö. Farkas, A. Perczel, I. Jakli, C.P. Sosa, I.G. Csizmadia, in preparation.